<PAGE>
===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
---------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
---------------------------------------
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): AUGUST 18, 2000
INTERMUNE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-29801 94-3296648
(State or other jurisdiction of (Commission File (I.R.S. Employer
incorporation or organization) Number) Identification No.)
1710 GILBRETH ROAD, SUITE 301, BURLINGAME, CALIFORNIA 94010
(Address of principal executive offices)
(650) 409-2020
(Registrant's telephone number, including area code)
---------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS
On August 18, 2000 InterMune Pharmaceuticals, Inc. (the "Company")
raised $76.0 million through a private placement of 2,000,000 shares of the
Company's common stock, par value $.001 per share (the "Offering"). Pursuant
to purchase agreements, dated August 11, 2000 (the "Purchase Agreements"),
between the Company and 19 institutional investors (the "Investors"), the
Company sold the shares for $38.00 per share. The shares have not been
registered under the Securities Act of 1933 (the "Act"). In connection with
the Offering, the Company has agreed to file a registration statement on Form
S-1 under the Act to register the resale of the shares purchased by the
Investors.
The form of the Purchase Agreements is attached to this Current
Report on Form 8-K and referenced as Exhibit 99.1. A copy of the Company's
press release announcing the transaction is attached to this Current Report
on Form 8-K as Exhibit 99.2
ITEM 7. EXHIBITS
Exhibit No. Description
---------- -----------
Exhibit 99.1 Form of common stock Purchase Agreement, dated
August 11, 2000, between the Company and Investors.
Exhibit 99.2 Press Release, dated August 17, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
InterMune Pharmaceuticals, Inc
(Registrant)
By: /s/ TIMOTHY P. LYNCH
---------------------------------
Vice President of Finance and
Administration and Chief Financial
Officer
August 23, 2000
<PAGE>
INDEX TO EXHIBITS
Exhibit No. Description
---------- -----------
Exhibit 99.1 Form of common stock Purchase Agreement, dated
August 11, 2000, between the Company and Investors.
Exhibit 99.2 Press Release, dated August 17, 2000.
